Exalenz Bioscience Ltd.

In the Media

Home > News & Events > In the Media

January 06, 2010
Exalenz finds positive news in Phase III study

Read more
December 14, 2009
Let`s Smell Your H. pylori! BreathID Racks Up New Positive Trial on Road to FDA Approval

Read more
December 10, 2008
Exalenz Reorganizes : Focuses on Existing Product

Read more
August 11, 2008
Exalenz succeeded in clinical trial to predict complications and death of liver patients

Read more
August 06, 2008
Exalenz signed an agreement with Pfizer for the use of the BreathID System

Read more
July 24, 2008
Grant received from BIRD Foundation for project for development of diagnostic tools for NASH disease

Read more
July 23, 2008
Exalenz will conduct clinical trials with the specialized material developed for the diagnosis of NASH disease

Read more
Completion of development of specialized material to diagnose NASH disease

Read more
July 21, 2008
Leader recommends Exalenz

Read more
July 21, 2008
Exalenz Completed the feasibility ( phase 2 ) trial for assessing hepatic impairment

Read more
July 21, 2008
Leader gives Exalenz target price set to 13 NIS, a 165% premium over current market price

Read more
June 20, 2008
Exalenz Receives FDA Apprval for Phase III Study

Read more
May 18, 2008
Chronic hepatitis C: A breath test to determine fibrosis

Read more
April 03, 2008
BreathID Sniffs Success, Eyes FDA Approval

Read more
April 02, 2008
Exalenz reports on succeeding in the liver function clinical trials and is preparing for submission to FDA

Read more
September 11, 2007
Mori Arkin Increases Involvement in BreathID, and is Appointed Chairman

Read more
September 10, 2007
BreathID will Place a System in Kings College Hospital in London

Read more
September 10, 2007
BreathID Expands Into Europe. Signs a Distribution Agreement in Benelux.

Read more
August 12, 2007
BreathID Signs 1.5M NIS Distribution Agreement

Read more
July 21, 2007
Arkin to increase BreathID stake

Read more
July 07, 2007
Jerusalem`s BreathID IPO is 37% oversubscribed

Read more
May 16, 2006
Breakthrough offers painless, instant liver test

Read more

2010 Exalenz Bioscience Ltd. All Rights Reserved

Developed by Moonsite

Disclaimer: In the USA, The BreathID System is intended for use in the qualitative detection of H. pylori. It has an approved 510(K) and an approved NDA for the ¹³ C-urea Tablet and Citrica Powder . Other applications are limited by Federal (of United States) Law to Investigational Use only. In Europe: The BreathID System has a CE approval for assessing Helicobacter pylori, Liver Function, and Gastric Emptying Rate.